T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response

Lignende værker

• Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment
  af: Kansy, Benjamin A, et al.
  Udgivet: (2015)
• PD-1 status in CD8(+) T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer
  af: Kansy, Benjamin A., et al.
  Udgivet: (2017)
• Level of PD-1 expression on CD8+ T cells influence prognosis and respond to PD-1 therapy in a murine model
  af: Kansy, Benjamin A, et al.
  Udgivet: (2015)
• STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV(+) status in head and neck cancer
  af: Lu, Shanhong, et al.
  Udgivet: (2018)
• A Phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC)
  af: Ferris, Robert L, et al.
  Udgivet: (2015)